Key result
CAC score may improve cardiovascular risk stratification in patients with HeFH.
Why the study?
Given the heterogeneity in CVD in patients with HeFH, tools such as the SAFEHEART-RE and CAC score may be useful for better risk stratification.
Observational (n=129)
Answers are grounded in this paper and cite their sources.
In patients with heterozygous familial hypercholesterolemia, delayed diagnosis and treatment initiation are associated with higher cumulative LDL-C burden and increased subclinical atherosclerosis as measured by CAC score.
Background Heterozygous familial hypercholesterolaemia (HeFH) confers a high risk of cardiovascular disease (CVD) due to elevated levels of LDL-cholesterol (LDL-C). The aim of this study is to assess the influence of clinical and genetic factors on coronary artery calcium (CAC) score in patients with HeFH.Methods CAC score were obtained for 129 genetically confirmed HeFH patients from NAGENCOL project, who had no CVD. Association of CAC with clinical and genetic variables as well as with the SAFEHEART-risk equation (SAFEHEART-RE) was evaluated.Results 65 patients had CAC = 0 (50.4%), 24 had CAC score between 1 and 99 (18.6%), and 40 had a score of ≥100 (31%). Individuals with a CAC score ≥100 were older (56.5 years vs. 39 years for those with a CAC score of 0, p < 0.001). They also had a higher prevalence of classical risk factors and history of CAD in the family. In addition, this group had higher maximum LDL-C levels (308.8 mg/dL vs. 262.5 mg/dL, p < 0.001), higher age at genetic diagnosis (45 years vs. 31.3, p < 0.001) and at the beginning of Treatment (34.5 years vs. 26.6, p = 0.002). Consequently, the cumulative LDL-C throughout their life was higher (13745.3 mg/dL vs. 8693.2 mg/dL, p < 0.001). There was a correlation between the results of the SAFEHEART-RE and CAC score.Conclusions Early diagnosis and early initiation of appropriate treatment are essential for reducing the accumulated cholesterol burden in patients with HeFH. Given the heterogeneity in CVD in patients with HeFH, tools such as the SAFEHEART-RE and CAC score may be useful for better risk stratification.
No takes yet. Share an insight, caveat, or question.
Lorea et al. (2025) conducted an observational in Heterozygous familial hypercholesterolemia (n=129). Clinical and genetic factors (including age and LDL-C burden) was evaluated on Coronary artery calcium (CAC) score. Among patients with HeFH, those with a CAC score ≥100 had significantly higher cumulative LDL-C (13745.3 vs 8693.2 mg/dL, p<0.001) and were older (56.5 vs 39 years, p<0.001) than those with CAC=0.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: